Yes.

Well, technically, he was, again, Chris Angels.

You had him on last week.

He saw something in Brian Stills when he was part of By Any Means.

They was constantly losing.

And like I said, Chris Angels saw something in him.

He brought him into the group.

So what's going to be your impact when all is said and done? What impact are you going to have when all is said and done?

So brokers and dealers

dealersCan go to any of their listing page, and then you can schedule a live stream, and then on the time everybody gets an email who's- You guys send the email out- Yeah, we send out it.

Yeah ... to everybody on, on- On our mailing list ... your platform.

Yes.

On your mailing list.

People that are interested in these kind of boats, and then- Right ... obviously industry professionals and whoever- Right ... is in that time zone, and then they get an email, and then they watch the live stream right from Yachtway.

Right.

[laughs] Listing platform drama?

I mean, w- with that Creator Network of 200 creators and, and a target of 500 original videos a month, h- how does this position DigitalBox for the next generation of digital media?

Well, it, it rap- uh, significantly changes the output.

I mean, typically, uh, we've been doing, let's say, 3,000 articles across the business a month or 2,500 articles across the business a month, which are more traditional text-based articles.

Um, moving into video will d- d- do two things.

One, it'll open up, uh, the ability for us to distribute, uh, branded content.

That's one thing.

So being able to distribute branded content in video form as well as a text-based article form, uh, will help us in our move towards a direct sale, uh, sell with clients.

Uh, l- looking ahead, what are the key milestones investors should watch as you roll out the Creator Network and, and return the business to growth?

Biology and story being one, but also when you get down into the biochemistry, there's some unusual factors, should we say.

Well, the important thing is that everyone's trying to do the best they can to help the patients.

And for a lot of reasons, a lot of cardiology care has been simplified.

for the purpose of finding a way to reach as many people as possible to guidelines and risk calculators.

Even though the evidence doesn't really show that that's effective, the incidence and prevalence of cardiovascular disease across the globe continues to rise, continues to be a burden.

And the reason for that is because we're not treating all of the risk.

And my presentation used papers and scientific articles that were peer-reviewed from major cardiology journals and major internal medicine journals.

What are some of the key biomarkers that you might look at to go a little bit deeper into the actual risk related to inflammation?